What is the most recent earnings date for VTGN stock?
VISTAGEN THERAPEUTICS INC (VTGN) last reported earnings on 2/12/2026.
VISTAGEN THERAPEUTICS INC (VTGN) Earnings History & Surprises
NASDAQ:VTGN • US92840H4002
Current stock price
0.5559 USD
+0.01 (+1.04%)
At close:
0.5503 USD
-0.01 (-1.01%)
Pre-Market:
VTGN Earnings overview
Past quarterly earnings results for VISTAGEN THERAPEUTICS INC (VTGN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- Jun 15, 2026
- Period
- Q4 / 2026
- EPS Estimate
- -$0.34
- Revenue Estimate
- 273.023K
Last Reported
Most Recent- Release Date
- Feb 12, 2026
- Period
- Q3 / 2026
- EPS Reported
- -$0.45
- EPS Surprise
- 9.22%
- Revenue Surprise
- -18.84%
Beat Rate
Last 8 Quarters 50%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2026 | -0.45 | -0.50 | 9.22% | 2.17% | 303K | 373.32K | -18.84% | 29.49% |
| Q2 2026 | -0.54 | -0.49 | -11.22% | -28.57% | 258K | 248.197K | 3.95% | 40.98% |
| Q1 2026 | -0.47 | -0.48 | 2.65% | -34.29% | 244K | 663K | -63.20% | 190.48% |
| Q4 2025 | -0.43 | -0.51 | 14.73% | -72.80% | 15K | 321.3K | -95.33% | -92.39% |
| Q3 2025 | -0.46 | -0.52 | 11.57% | -109.09% | 234K | 183.6K | 27.45% | -43.12% |
| Q2 2025 | -0.42 | -0.40 | -5.58% | 36.36% | 183K | 227.797K | -19.67% | -34.10% |
| Q1 2025 | -0.35 | -0.41 | 15.27% | -1,043.79% | 84K | 306K | -72.55% | -53.33% |
| Q4 2024 | -0.25 | -0.37 | 32.39% | 85.71% | 197K | 206.805K | -4.74% | 12.19% |
| Q3 2024 | -0.22 | -0.31 | 28.70% | 85.33% | 411.4K | 555.39K | -25.93% | 128.56% |
| Q2 2024 | -0.66 | -0.69 | 4.84% | 72.50% | 277.7K | 181.56K | 52.95% | 131.20% |
| Q1 2024 | -0.03 | - | 98.98% | 180K | 188.7K | -4.61% | -41.94% | |
| Q4 2023 | -1.75 | -1.53 | -14.38% | 35.19% | 175.6K | - | 339.00% | |
| Q3 2023 | -1.50 | -2.14 | 29.97% | - | 180K | 158.1K | 13.85% | -50.00% |
| Q2 2023 | -2.40 | -2.04 | -17.64% | -14.29% | -890K | 316.2K | -381.47% | -347.22% |
| Q1 2023 | -3.00 | -2.30 | -30.72% | -150.00% | 310K | 345.27K | -10.22% | -11.43% |
| Q4 2022 | -2.70 | -1.76 | -53.45% | 55.00% | 40K | 359.723K | -88.88% | -90.91% |
| Q3 2022 | -1.50 | -2.22 | 32.39% | 28.57% | 360K | 259.08K | 38.95% | 16.13% |
| Q2 2022 | -2.10 | -1.76 | -19.35% | -40.00% | 360K | 268.77K | 33.94% | 9.09% |
| Q1 2022 | -1.20 | -1.63 | 26.47% | 42.86% | 350K | 388.283K | -9.86% | - |
| Q4 2021 | -6.00 | -1.53 | -292.16% | -185.71% | 440K | 233.07K | 88.78% | - |
| Q3 2021 | -2.10 | -1.63 | -28.68% | 53.33% | 310K | 215.557K | 43.81% | - |
| Q2 2021 | -1.50 | -0.71 | -110.11% | 61.54% | 330K | 1.7M | -80.59% | - |
| Q1 2021 | -2.10 | -3.83 | 45.10% | 53.33% | - | - | ||
| Q4 2020 | -2.10 | -2.45 | 14.22% | - | - | - | ||
| Q3 2020 | -4.50 | -2.14 | -110.08% | - | - | - | ||
| Q2 2020 | -3.90 | -4.13 | 5.59% | - | - | - | ||
| Q1 2020 | -4.50 | -3.37 | -33.69% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
3.84%
Max EPS beat (4)
14.73%
Min EPS beat (4)
-11.22%
Revenue beat statistics
Revenue beat (4)
1
Average Revenue beat (4)
-43.35%
Max Revenue beat (4)
3.95%
Min Revenue beat (4)
-95.33%
Analysis
In the last 4 quarters, VTGN has beaten EPS estimates in 3 out of 4 releases
VTGN has beaten revenue estimates in 1 out of the last 4 releases
In the last 4 quarters, VTGN has beaten the EPS estimates by 3.8% on average.
In the last 4 quarters, VTGN reported -43.4% below the revenue estimates on average.
Related analysis
VISTAGEN THERAPEUTICS INC / VTGN Earnings FAQ
Can you provide information on whether VISTAGEN THERAPEUTICS INC beat earnings estimates in the last quarter?
VISTAGEN THERAPEUTICS INC (VTGN) beat EPS estimates and missed revenue estimates in the most recent quarter.
What percentage of the time does VTGN stock beat earnings estimates?
In the last 4 quarters, VISTAGEN THERAPEUTICS INC (VTGN) has beaten EPS estimates in 3 out of 4 releases.